SCHEMBL4680699

SCHEMBL4680699

O=C(NCc1cc(-c2ccc(F)c(F)c2)no1)c1ccon1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.48
SMN1; SMN2 Q16637 4/20 0.47
HTT P42858 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
ALDH1A1 P00352 2/20 0.47
JAK2 O60674 1/20 0.47
LMNA P02545 2/20 0.46
THRB P10828 2/20 0.45
MAPT P10636 1/20 0.45
CYP1A2 P05177 1/20 0.44
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
MAPK1 P28482 1/20 0.43
EPHX2 P34913 2/20 0.43
KMT2A Q03164 1/20 0.41
SUCNR1 Q9BXA5 2/20 0.40
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3591952 0.81 POLB (0.72) POLBSMN1; SMN2HTTL3MBTL1ALDH1A1
SCHEMBL3582885 0.77 IGF1R (0.46) POLBSMN1; SMN2HTTL3MBTL1ALDH1A1
SCHEMBL6407414 0.72 MAPT (0.47) POLBSMN1; SMN2HTTL3MBTL1ALDH1A1
SCHEMBL4686166 0.72 KMO (0.40) POLBSMN1; SMN2HTTL3MBTL1ALDH1A1
SCHEMBL4683349 0.72 NOTUM (0.66) POLBSMN1; SMN2HTTL3MBTL1ALDH1A1
SCHEMBL4684429 0.69 NOTUM (0.66) POLBSMN1; SMN2HTTL3MBTL1ALDH1A1
SCHEMBL31036973 0.68 ALDH1A1 (0.45) POLBSMN1; SMN2HTTL3MBTL1ALDH1A1
SCHEMBL6404893 0.68 ROCK2 (0.56) POLBSMN1; SMN2HTTL3MBTL1ALDH1A1
SCHEMBL6403578 0.68 EPHX2 (0.54) POLBSMN1; SMN2HTTL3MBTL1ALDH1A1
SCHEMBL6409969 0.67 POLB (0.50) POLBSMN1; SMN2HTTL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1437349-B9 SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS S A L V A T LAB SA (ES) 2008-09-10 EP disclosed
EP-1437349-B1 SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS S A L V A T LAB SA (ES) 2007-08-15 EP disclosed
US-20050014806-A1 Substituted isoxazoles and their use as antibiotics LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2005-01-20 US disclosed
EP-1437349-A1 SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2004-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014806-A1 Substituted isoxazoles and their use as antibiotics XDH, SCO2, HAX1 POLB 1162/4885SMN1; SMN2 3326/4885HTT 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.